Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trials

Toregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The drug targets a protein that suppresses tooth growth, aiming to stimulate dormant tooth buds. Initial trials focus on children with congenital tooth agenesis, with potential future applications for tooth loss due to aging or injury.

Raccontata daeconomictimes.indiatimes.com